LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global interferons market and the market is poised to grow by USD 660.34 million during 2019-2023 at a CAGR of almost 2% during the forecast period. Request Free Sample Pages
Read the 126-page research report with TOC on "Interferons Market Analysis Report by type (interferon beta, interferon alfa, and other interferons), by geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023".
The market is driven by the advent of novel drug delivery and combination therapies. In addition, the advent of biosimilars is anticipated to further boost the growth of the interferons market.
The administration of interferons through the intravenous RoA causes side-effects such as irritation, redness, and swelling at the injection site. It also increases the risk of extravasation. This is driving the need for novel drug delivery systems to provide the minimum dose with the maximum benefit. Novel drug delivery systems deliver interferons to the target site for improved treatment efficacy. Thus, the advent of novel drug delivery methods is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Interferons Market Companies:
Bayer AG
Bayer AG is headquartered in Germany and operates the business under various business segments such as Pharmaceuticals, Consumer health, Crop science, and Animal health. The company offers BETASERON, which is produced by recombinant DNA techniques.
Biogen
Biogen is headquartered in the US and offers products through the segment: Pharmaceuticals. The company offers AVONEX and PLEGRIDY for people living with serious neurological and neurodegenerative diseases.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. is headquartered in Switzerland and has business operations under various business segments, namely Pharmaceuticals and Diagnostics. The company offers PEGASYS and ROFERON-A.
Merck KGaA
Merck KGaA is headquartered in Germany and offers products through the following business segments: Healthcare, Life sciences, and Performance materials. The company offers Rebif, which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. is headquartered in the US and offers products through the following business segments: Pharmaceutical, Animal health, Healthcare services, and Alliances. The company offers INTRON A and SYLATRON.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Interferons Type Outlook (Revenue, USD Million, 2019 - 2023)
- Interferon beta
- Interferon alfa
- Other interferons
Interferons Regional Outlook (Revenue, USD Million, 2019 - 2023)
- Asia
- Europe
- North America
- ROW
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care are:
Antifreeze Proteins Market – Global Antifreeze Proteins Market by application (healthcare, cosmetics, F&B, and others) and geography (APAC, Europe, North America, and ROW).
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market – Global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by type (monotherapy and combination therapy) and geography (Asia, Europe, North America, and ROW).
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
